• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Obesity and Venous Disease: An Expert Discussion


Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.

“Obesity is an independent and moderate risk factor for venous thromboembolism, which was the driving force behind co-authoring this clinical practice statement," Shagun Bindlish, MD, medical director at One Medical, in Dublin, California and associate editor for the Obesity Medicine Association’s new journal Obesity Pillars, said in an interview with Patient Care Online. "We wanted to highlight some of the important complications and the clinical tools that will help clinicians assess and treat their patients with obesity and thromboembolism."

The clinical practice statement is titled Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: An obesity medicine association (OMA) clinical practice statement (CPS) 2023, and was published in the December 2023 issue of Obesity Pillars. In the video below, Bindlish discusses the impetus for development of the guidance document.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.